Virologically confirmed (RT-PCR-positive) symptomatic COVID-19 cases of any severity that occurs for the first time at least 7 days (>= 8 days) after the second vaccination.;All serious adverse events (SAEs); other medically attended AEs (MAAEs); and adverse events of special interest (AESIs) from the first dose to 12 months after the second dose in all subjects;All solicited adverse events within 7 days following the first and second vaccinations in all subjects;All unsolicited adverse events that occur during the interval between doses and within 30 days after the second vaccination in all subjects;

Virologically confirmed (RT-PCR-positive) symptomatic COVID-19 cases of any severity that occurs for the first time at least 7 days (>= 8 days) after the second vaccination.;All serious adverse events (SAEs); other medically attended AEs (MAAEs); and adverse events of special interest (AESIs) from the first dose to 12 months after the second dose in all subjects;All solicited adverse events within 7 days following the first and second vaccinations in all subjects;All unsolicited adverse events that occur during the interval between doses and within 30 days after the second vaccination in all subjects;

Virologically confirmed (RT-PCR-positive) symptomatic COVID-19 cases of any severity that occurs for the first time at least 7 days (= 8 days) after the second vaccination.;All serious adverse events (SAEs); other medically attended AEs (MAAEs); and adverse events of special interest (AESIs) from the first dose to 12 months after the second dose in all subjects;All solicited adverse events within 7 days following the first and second vaccinations in all subjects;All unsolicited adverse events that occur during the interval between doses and within 30 days after the second vaccination in all subjects;

Virologically confirmed (RT-PCR-positive) symptomatic COVID-19 cases of any severity that occurs for the first time at least 7 days (= 8 days) after the second vaccination.;All serious adverse events (SAEs); other medically attended AEs (MAAEs); and adverse events of special interest (AESIs) from the first dose to 12 months after the second dose in all subjects;All solicited adverse events within 7 days following the first and second vaccinations in all subjects;All unsolicited adverse events that occur during the interval between doses and within 30 days after the second vaccination in all subjects;